# Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome

Study · id `cardio:ct-nct06723002` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06723002](<https://clinicaltrials.gov/study/NCT06723002>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06723002

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06723002. Randomized; double masking; primary purpose treatment. Start 2024-12-01 (anticipated); primary completion 2025-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06723002, source copy `cardio:ctgov-nct06723002-2024-12-09`, retrieved 2026-10-31)
- Planned start: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT06723002, source copy `cardio:ctgov-nct06723002-2024-12-09`, retrieved 2026-10-31)
- Primary completion: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT06723002, source copy `cardio:ctgov-nct06723002-2024-12-09`, retrieved 2026-10-31)
- Completion: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT06723002, source copy `cardio:ctgov-nct06723002-2024-12-09`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06723002-2024-12-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
- Acronym: ACS\_ATHEROLIV
- Condition: Acute Coronary Syndrome (ACS)
- Condition: Reactive Hyperemia
- Condition: Endothelial Dysfunction
- Intervention (Drug): Atherolive 500mg/day
- Intervention (Drug): Atherolive 1000/day
- Intervention (Drug): Placbo\_Atherolive
- Lead sponsor: University of Monastir
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: University of Monastir (`cardio:org-university-of-monastir`)

## Provenance

Content hash: d8066097093ee7275f1bde3b963fff582a2c397bef20e4c2f9b2e19de2582761
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
